These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 30902669)

  • 41. Cannabis-related psychotic disorder upon relapse to cannabis use: A case series and possible neurobiological implications.
    Bharadwaj B; Navin K; Kuppili PP
    Asian J Psychiatr; 2018 Mar; 33():42-44. PubMed ID: 29524790
    [No Abstract]   [Full Text] [Related]  

  • 42. Timing of cannabis exposure relative to prodrome and psychosis onset in a community-based first episode psychosis sample.
    Kline ER; Ferrara M; Li F; D'Souza DC; Keshavan M; Srihari VH
    J Psychiatr Res; 2022 Mar; 147():248-253. PubMed ID: 35066293
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Cannabis consumption and development of psychosis: state of the art].
    Roncero C; Collazos F; Valero S; Casas M
    Actas Esp Psiquiatr; 2007; 35(3):182-9. PubMed ID: 17508295
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cannabis use and psychotic disorders in diverse settings in the Global South: findings from INTREPID II.
    Lee Pow J; Donald C; di Forti M; Roberts T; Weiss HA; Ayinde O; John S; Olley B; Ojagbemi A; Esponda GM; Lam J; Poornachandrika P; Dazzan P; Gaughran F; Kannan PP; Sudhakar S; Burns J; Chiliza B; ; Cohen A; Gureje O; Thara R; Murray RM; Morgan C; Hutchinson G
    Psychol Med; 2023 Nov; 53(15):7062-7069. PubMed ID: 36951137
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Higher average potency across the United States is associated with progression to first cannabis use disorder symptom.
    Arterberry BJ; Treloar Padovano H; Foster KT; Zucker RA; Hicks BM
    Drug Alcohol Depend; 2019 Feb; 195():186-192. PubMed ID: 30573162
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cannabis use influences disorganized symptoms severity but not transition in a cohort of non-help-seeking individuals at-risk for psychosis from São Paulo, Brazil.
    de Medeiros MW; Andrade JC; Haddad NM; Mendonça M; de Jesus LP; Fekih-Romdhane F; van de Bilt MT; Gattaz WF; Loch AA
    Psychiatry Res; 2024 Jan; 331():115665. PubMed ID: 38113810
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Changing Legal Landscape of Cannabis Use and Its Role in Youth-onset Psychosis.
    Wright A; Cather C; Gilman J; Evins AE
    Child Adolesc Psychiatr Clin N Am; 2020 Jan; 29(1):145-156. PubMed ID: 31708043
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The EUropean Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI): Incidence and First-Episode Case-Control Programme.
    Gayer-Anderson C; Jongsma HE; Di Forti M; Quattrone D; Velthorst E; de Haan L; Selten JP; Szöke A; Llorca PM; Tortelli A; Arango C; Bobes J; Bernardo M; Sanjuán J; Santos JL; Arrojo M; Parellada M; Tarricone I; Berardi D; Ruggeri M; Lasalvia A; Ferraro L; La Cascia C; La Barbera D; Menezes PR; Del-Ben CM; ; Rutten BP; van Os J; Jones PB; Murray RM; Kirkbride JB; Morgan C
    Soc Psychiatry Psychiatr Epidemiol; 2020 May; 55(5):645-657. PubMed ID: 31974809
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of High-Potency Cannabis Use With Mental Health and Substance Use in Adolescence.
    Hines LA; Freeman TP; Gage SH; Zammit S; Hickman M; Cannon M; Munafo M; MacLeod J; Heron J
    JAMA Psychiatry; 2020 Oct; 77(10):1044-1051. PubMed ID: 32459328
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Use of Cannabis and incidence of psychotic symptoms: Evidence from Buenos Aires].
    Barrera Á; Rocha MP; Leiderman E
    Vertex; 2016 Nov; XXVII(130):447-451. PubMed ID: 28898304
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cannabis with high cannabidiol content is associated with fewer psychotic experiences.
    Schubart CD; Sommer IE; van Gastel WA; Goetgebuer RL; Kahn RS; Boks MP
    Schizophr Res; 2011 Aug; 130(1-3):216-21. PubMed ID: 21592732
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Effect of Changes in Cannabis Exposure on Psychotic Symptoms in Patients With Comorbid Cannabis Use Disorder.
    Toftdahl NG; Nordentoft M; Hjorthøj C
    J Dual Diagn; 2016; 12(2):129-36. PubMed ID: 27070732
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use.
    Ferraro L; La Cascia C; Quattrone D; Sideli L; Matranga D; Capuccio V; Tripoli G; Gayer-Anderson C; Morgan C; Sami MB; Sham P; de Haan L; Velthorst E; Jongsma HE; Kirkbride JB; Rutten BPF; Richards AL; Roldan L; Arango C; Bernardo M; Bobes J; Sanjuan J; Santos JL; Arrojo M; Tarricone I; Tortelli A; Szöke A; Del-Ben CM; Selten JP; Lynskey M; Jones PB; Van Os J; La Barbera D; ; Murray RM; Di Forti M
    Schizophr Bull; 2020 Apr; 46(3):517-529. PubMed ID: 31361020
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: a cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study.
    Jauhar S; McCutcheon R; Borgan F; Veronese M; Nour M; Pepper F; Rogdaki M; Stone J; Egerton A; Turkheimer F; McGuire P; Howes OD
    Lancet Psychiatry; 2018 Oct; 5(10):816-823. PubMed ID: 30236864
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comorbid Cannabis and Tobacco Use Disorders in Hospitalized Patients with Psychotic-Spectrum Disorders.
    Reeves LE; Gaudiano BA; Metrik J; Guzman Holst C; Morena A; Sydnor VJ; Weinstock LM; Epstein-Lubow G
    J Dual Diagn; 2018; 14(3):171-180. PubMed ID: 30265850
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Potential Impact of Recreational Cannabis Legalization on the Prevalence of Cannabis Use Disorder and Psychotic Disorders: A Retrospective Observational Study.
    Vignault C; Massé A; Gouron D; Quintin J; Asli KD; Semaan W
    Can J Psychiatry; 2021 Dec; 66(12):1069-1076. PubMed ID: 33567893
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and timeline follow-back (TLFB)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomized clinical trial.
    Hjorthøj CR; Fohlmann A; Larsen AM; Arendt M; Nordentoft M
    Addiction; 2012 Jun; 107(6):1123-31. PubMed ID: 22151583
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Public health monitoring of cannabis use in Europe: prevalence of use, cannabis potency, and treatment rates.
    Manthey J; Freeman TP; Kilian C; López-Pelayo H; Rehm J
    Lancet Reg Health Eur; 2021 Nov; 10():100227. PubMed ID: 34806072
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tests of causal linkages between cannabis use and psychotic symptoms.
    Fergusson DM; Horwood LJ; Ridder EM
    Addiction; 2005 Mar; 100(3):354-66. PubMed ID: 15733249
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The relationship between cannabis use, schizophrenia, and bipolar disorder: a genetically informed study.
    Cheng W; Parker N; Karadag N; Koch E; Hindley G; Icick R; Shadrin A; O'Connell KS; Bjella T; Bahrami S; Rahman Z; Tesfaye M; Jaholkowski P; Rødevand L; Holen B; Lagerberg TV; Steen NE; Djurovic S; Dale AM; Frei O; Smeland OB; Andreassen OA
    Lancet Psychiatry; 2023 Jun; 10(6):441-451. PubMed ID: 37208114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.